248 related articles for article (PubMed ID: 37417254)
1. Application of physiologically based pharmacokinetic modeling to understand real-world outcomes in patients receiving imatinib for chronic myeloid leukemia.
Adattini JA; Adiwidjaja J; Gross AS; McLachlan AJ
Pharmacol Res Perspect; 2023 Aug; 11(4):e01082. PubMed ID: 37417254
[TBL] [Abstract][Full Text] [Related]
2. CYP2C8 Genotype Significantly Alters Imatinib Metabolism in Chronic Myeloid Leukaemia Patients.
Barratt DT; Cox HK; Menelaou A; Yeung DT; White DL; Hughes TP; Somogyi AA
Clin Pharmacokinet; 2017 Aug; 56(8):977-985. PubMed ID: 27995529
[TBL] [Abstract][Full Text] [Related]
3. Potential for pharmacokinetic interactions between Schisandra sphenanthera and bosutinib, but not imatinib: in vitro metabolism study combined with a physiologically-based pharmacokinetic modelling approach.
Adiwidjaja J; Boddy AV; McLachlan AJ
Br J Clin Pharmacol; 2020 Oct; 86(10):2080-2094. PubMed ID: 32250458
[TBL] [Abstract][Full Text] [Related]
4. In Vivo Cytochrome P450 3A Isoenzyme Activity and Pharmacokinetics of Imatinib in Relation to Therapeutic Outcome in Patients With Chronic Myeloid Leukemia.
Skoglund K; Richter J; Olsson-Strömberg U; Bergquist J; Aluthgedara W; Ubhayasekera SJ; Vikingsson S; Svedberg A; Söderlund S; Sandstedt A; Johnsson A; Aagesen J; Alsenhed J; Hägg S; Peterson C; Lotfi K; Gréen H
Ther Drug Monit; 2016 Apr; 38(2):230-8. PubMed ID: 26693810
[TBL] [Abstract][Full Text] [Related]
5. Population Pharmacokinetics of Imatinib in Nigerians With Chronic Myeloid Leukemia: Clinical Implications for Dosing and Resistance.
Adeagbo BA; Olugbade TA; Durosinmi MA; Bolarinwa RA; Ogungbenro K; Bolaji OO
J Clin Pharmacol; 2017 Dec; 57(12):1554-1563. PubMed ID: 28618035
[TBL] [Abstract][Full Text] [Related]
6. Predictive value of early molecular response for deep molecular response in chronic phase of chronic myeloid leukemia.
Wang R; Cong Y; Li C; Zhang C; Lin H
Medicine (Baltimore); 2019 Apr; 98(15):e15222. PubMed ID: 30985724
[TBL] [Abstract][Full Text] [Related]
7. Implementation of a Physiologically Based Pharmacokinetic Modeling Approach to Guide Optimal Dosing Regimens for Imatinib and Potential Drug Interactions in Paediatrics.
Adiwidjaja J; Boddy AV; McLachlan AJ
Front Pharmacol; 2019; 10():1672. PubMed ID: 32082165
[TBL] [Abstract][Full Text] [Related]
8. Influence of CYP2C8 polymorphisms on imatinib steady-state trough level in chronic myeloid leukemia and gastrointestinal stromal tumor patients.
Verboom MC; Visser L; Kouwen S; Swen JJ; Diepstraten J; Posthuma WF; Gelderblom H; van Lammeren D; Wilms EB
Pharmacogenet Genomics; 2017 Jun; 27(6):223-226. PubMed ID: 28383355
[TBL] [Abstract][Full Text] [Related]
9. Physiologically-Based Pharmacokinetic Predictions of the Effect of Curcumin on Metabolism of Imatinib and Bosutinib: In Vitro and In Vivo Disconnect.
Adiwidjaja J; Boddy AV; McLachlan AJ
Pharm Res; 2020 Jun; 37(7):128. PubMed ID: 32529309
[TBL] [Abstract][Full Text] [Related]
10. Physiologically-based pharmacokinetic model predictions of inter-ethnic differences in imatinib pharmacokinetics and dosing regimens.
Adiwidjaja J; Gross AS; Boddy AV; McLachlan AJ
Br J Clin Pharmacol; 2022 Feb; 88(4):1735-1750. PubMed ID: 34535920
[TBL] [Abstract][Full Text] [Related]
11. Role of ADME gene polymorphisms on imatinib disposition: results from a population pharmacokinetic study in chronic myeloid leukaemia.
Shriyan B; Mehta P; Patil A; Jadhav S; Kumar S; Puri AS; Govalkar R; Krishnamurthy MN; Punatar S; Gokarn A; Khattry N; Gota V
Eur J Clin Pharmacol; 2022 Aug; 78(8):1321-1330. PubMed ID: 35652931
[TBL] [Abstract][Full Text] [Related]
12. Influence of CYP3A5*3 and ABCB1 C3435T on clinical outcomes and trough plasma concentrations of imatinib in Nigerians with chronic myeloid leukaemia.
Adeagbo BA; Bolaji OO; Olugbade TA; Durosinmi MA; Bolarinwa RA; Masimirembwa C
J Clin Pharm Ther; 2016 Oct; 41(5):546-51. PubMed ID: 27426203
[TBL] [Abstract][Full Text] [Related]
13. Imatinib dose optimization based on therapeutic drug monitoring in Chinese patients with chronic-phase chronic myeloid leukemia.
Cheng F; Zeng F; Li Q; Cui Z; Chen Y; Li W; Zhang Y
Cancer; 2022 Nov; 128(22):3951-3958. PubMed ID: 36181667
[TBL] [Abstract][Full Text] [Related]
14. A study to explore the correlation of ABCB1, ABCG2, OCT1 genetic polymorphisms and trough level concentration with imatinib mesylate-induced thrombocytopenia in chronic myeloid leukemia patients.
Francis J; Dubashi B; Sundaram R; Pradhan SC; Chandrasekaran A
Cancer Chemother Pharmacol; 2015 Dec; 76(6):1185-9. PubMed ID: 26546461
[TBL] [Abstract][Full Text] [Related]
15. Utility of Therapeutic Drug Monitoring of Imatinib, Nilotinib, and Dasatinib in Chronic Myeloid Leukemia: A Systematic Review and Meta-analysis.
García-Ferrer M; Wojnicz A; Mejía G; Koller D; Zubiaur P; Abad-Santos F
Clin Ther; 2019 Dec; 41(12):2558-2570.e7. PubMed ID: 31812340
[TBL] [Abstract][Full Text] [Related]
16. Population Pharmacokinetic Analysis of the Oral Absorption Process and Explaining Intra-Subject Variability in Plasma Exposures of Imatinib in Healthy Volunteers.
Golabchifar AA; Rezaee S; Dinan NM; Kebriaeezadeh A; Rouini MR
Eur J Drug Metab Pharmacokinet; 2016 Oct; 41(5):527-39. PubMed ID: 26189007
[TBL] [Abstract][Full Text] [Related]
17. Nilotinib: a second-generation tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia.
Deremer DL; Ustun C; Natarajan K
Clin Ther; 2008 Nov; 30(11):1956-75. PubMed ID: 19108785
[TBL] [Abstract][Full Text] [Related]
18. Relationship between trough level of tyrosine kinase inhibitor (imatinib and nilotinib) and BCR-ABL ratios in an Indonesian chronic-phase chronic myeloid leukemia (CML) population.
Suprapti B; Andarsari MR; Hapsari PP; Khotib J; ; Bintoro SUY
J Basic Clin Physiol Pharmacol; 2020 Aug; 31(5):. PubMed ID: 32764164
[TBL] [Abstract][Full Text] [Related]
19. Analysis of adverse drug reactions of imatinib in chronic myeloid leukemia patients: An Eastern Indian experience.
Swain TR; Goutam S; Jena RK; Rout N
Indian J Pharmacol; 2022; 54(5):349-352. PubMed ID: 36537404
[TBL] [Abstract][Full Text] [Related]
20. Real-world Imatinib Mesylate Treatment in Patients with Chronic Myeloid Leukemia: The Importance of Molecular Monitoring and the Early Molecular Response.
Ferreira APS; Seguro FS; Abdo ARN; Santos FM; Maciel FVR; Nardinelli L; Giorgi RR; Ruiz ARL; Ferreira MPS; Rego EM; Rocha V; Bendit I
Ann Hematol; 2023 Jul; 102(7):1761-1771. PubMed ID: 37052662
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
